Merus highlighted preclinical results of zenocutuzumab, HER2 × HER3 bispecific antibody, in 28 patient-derived xenograft (PDX) NRG1 expressing cancer models with 21 tumor types where zenocutuzumab demonstrated tumor growth inhibition among 7/28 PDX models
In preclinical study, zenocutuzumab inhibited the N87 gastric cancer & SKBR-3 breast cancer cell lines’ proliferation at high concentrations of NRG1. It further inhibited the NRG1-amplified HCC95 lung cancer cell line proliferation, blocking the signals controlling cell growth & survival
The above results confirmed the efficacy of zenocutuzumab tumor cell destruction in vitro and in vivo among cancer models expressing NRG1
Ref: Merus | Image: Merus
Related News:- Merus’ Zenocutuzumab Receives the US FDA’s Breakthrough Therapy Designation for NRG1 Fusion Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
